ArticleFrontiers in neuroscience2020
Astragalin Alleviates Neuropathic Pain by Suppressing P2X4-Mediated Signaling in the Dorsal Root Ganglia of Rats.
Article in Frontiers in neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Exploring the therapeutic potential of Astragalin in Parkinson's disease: a network pharmacology approach.Annals of medicine and surgery (2012) · 2026Article
- Astragalin relieves inflammatory pain and negative mood in CFA mice by down-regulating mGluR5 signaling pathway.Scientific reports · 2025Article
- Review
- Mahuang Fuzi Xixin decoction: A potent analgesic for neuropathic pain targeting the NMDAR2B/CaMKIIα/ERK/CREB pathway.Heliyon · 2024Article
- Diabetic Neuropathic Pain and Circadian Rhythm: A Future Direction Worthy of Study.Journal of pain research · 2024Review
- Naringin inhibits P2X4 receptor expression on satellite glial cells in the neonatal rat dorsal root ganglion.Journal of applied biomedicine · 2023Article
- Purinergic signaling: a potential therapeutic target for depression and chronic pain.Purinergic signalling · 2023Review
- Astragalin: a food-origin flavonoid with therapeutic effect for multiple diseases.Frontiers in pharmacology · 2023Review
- Modulation of P2XPhysiological reports · 2022Article
- The Role of Microglial Purinergic Receptors in Pain Signaling.Molecules (Basel, Switzerland) · 2022Review
- Modulation of Neuropathic Pain by Glial Regulation in the Insular Cortex of Rats.Frontiers in molecular neuroscience · 2022Article
- Single-cell RNA sequencing reveals distinct transcriptional features of the purinergic signaling in mouse trigeminal ganglion.Frontiers in molecular neuroscience · 2022Article
- Emerging roles of circular RNAs in neuropathic pain.Cell proliferation · 2021Review
- Targeting P2 receptors in purinergic signaling: a new strategy of active ingredients in traditional Chinese herbals for diseases treatment.Purinergic signalling · 2021Review
- Novel Nanotechnological Approaches for Targeting Dorsal Root Ganglion (DRG) in Mitigating Diabetic Neuropathic Pain (DNP).Frontiers in endocrinology · 2021Review
- Plant-derived natural products targeting ion channels for pain.Neurobiology of pain (Cambridge, Mass.)Review
- Physiological actions of a humanized P2X4 scFv on peripheral and central neurons in male mice with neuropathic pain.Neurobiology of pain (Cambridge, Mass.)Article
- Humanized anti-P2X4 scFv reduces ATP-induced P2X4 currents and modulates excitability in human DRG neurons.Molecular painArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurologic damage often leads to neuropathic pain, for which there are no effective treatments owing to its complex pathogenesis. The purinergic receptor P2X4 is closely associated with neuropathic pain. Astragalin (AST), a compound that is used in traditional Chinese medicine, has protective effects against allergic dermatitis and neuronal injury, but its mechanism of action is not well understood. The present study investigated whether AST can alleviate neuropathic pain in a rat model established by chronic constriction injury (CCI) to the sciatic nerve. The model rats exhibited pain behavior and showed increased expression of P2X4 and the activated satellite glial cell (SGC) marker glial fibrillary acidic protein in dorsal root ganglia (DRG). AST treatment partly abrogated the upregulation of P2X4, inhibited SGC activation, and alleviated pain behavior in CCI rats; it also suppressed ATP-activated currents in HEK293 cells overexpressing P2X4. These data demonstrate that AST relieves neuropathic pain by inhibiting P2X4 and SGC activation in DRG, highlighting its therapeutic potential for clinical pain management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.